FDA Clears AI-Based Type 2 Diabetes Clinical Decision Support System

January 4, 2022

In October, DreaMed Diabetes AI LTD. announced that it received its fourth U.S. Food and Drug Administration (FDA) clearance for its Advisor Pro AI Clinical Decision Support System, which expands the platform’s target population to patients with both type 1 and type 2 diabetes. Advisor Pro is a decision support system cleared to assist healthcare providers […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

Diabetes

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today

RELATED ARTICLES

Heroin Adulterated with Diabetes Medication Triggers Life-Threatening Medical Emergencies

Hyperinsulinemia Emerges as Critical Predictor of Severe Liver Outcomes

Father’s Tobacco Use May Raise Children’s Diabetes Risk

Health Topics

Patient Populations